Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10646	Companies
226482	Keywords
154956	Articles
119883	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 06/23/2025 at 15:00, 1 year ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding

Crofelemer Jaguar Health Phase 2 Study MVID Intestinal Failure
BRIEF

published on 06/17/2025 at 15:05, 1 year ago

Jaguar Health participera à la conférence Emerging Growth

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Conférence Sur La Croissance Émergente
BRIEF

published on 06/17/2025 at 15:05, 1 year ago

Jaguar Health to Present at Emerging Growth Conference

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference
PRESS RELEASE

published on 06/17/2025 at 15:00, 1 year ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRIEF

published on 06/11/2025 at 16:05, 1 year ago

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 06/11/2025 at 16:05, 1 year ago

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
PRESS RELEASE

published on 06/11/2025 at 16:00, 1 year ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 1 year ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
BRIEF

published on 06/09/2025 at 22:20, 1 year ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
PRESS RELEASE

published on 06/09/2025 at 22:15, 1 year ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population

Accesswire

Published on 06/26/2026 at 15:05, 1 hour 58 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 2 hours 58 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 3 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 3 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 18 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 16:38, 25 minutes ago

Cairn Homes Plc: Notice of H1 2026 Trading Update
Published on 06/26/2026 at 15:30, 1 hour 33 minutes ago

JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc

Les Echos

Published on 06/26/2026 at 14:44, 2 hours 19 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 2 hours 19 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 4 hours 47 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 10 hours 3 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 3 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE